AUPH vs GSK: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: GSK is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. AUPH and GSK share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined AUPH and GSK exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Aurinia Pharmaceuticals is a commercial-stage biopharmaceutical company whose flagship product is LUPKYNIS (voclosporin), approved by the FDA in January 2021 as the first oral therapy for adult patients with active lupus nephritis, a form of kidney inflammation caused by lupus. That approval gave Aurinia a differentiated position: LUPKYNIS is the only approved oral treatment specifically for the condition, and it is also approved in Japan and marketed in Europe with partners. Unlike most small biotechs, Aurinia has turned this single product into a genuinely profitable, cash-generative business, reporting revenue growth in the 20% to 34% range in recent years, LUPKYNIS net product sales that continued climbing, positive net income, meaningful operating cash flow, and a substantial cash and investments balance.

Full AUPH guide

GSK plc is a UK-headquartered global biopharma company, one of the largest by revenue, focused on preventing and treating disease through vaccines, specialty medicines, and general medicines. It reorganized in 2022 when it spun off its consumer health arm as Haleon, leaving GSK as a pure biopharma business. Its most durable franchises are vaccines, led by the shingles vaccine Shingrix and the newer RSV vaccine Arexvy, and HIV, which it manages largely through the ViiV Healthcare joint venture with a shift toward long-acting injectable regimens. It also has growing positions in respiratory, immunology and inflammation, and oncology.

Full GSK guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• AUPH drivers: LUPKYNIS growth and exclusivity; Profitability and cash returns.
• GSK drivers: Vaccines franchise durability; HIV and long-acting injectables.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The dominant risk is single-product concentration: with revenue and profits driven overwhelmingly by LUPKYNIS, any setback in sales, reimbursement, safety, or exclusivity would hit the whole business, since there is no diversified portfolio to cushion it. For GSK, the central risk is the patent cliff and pipeline dependence: maturing products face generic and biosimilar competition, and the longer-term case relies on newer launches replacing that revenue, which is never guaranteed in drug development.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick AUPH if you believe its drivers more; GSK if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the AUPH and GSK guides.

AUPH. These figures are qualitative and tied to the asOf date; verify live revenue, earnings, cash, and per-share numbers with Aurinia's latest filings before acting. Some headline net-income figures have been boosted by one-time items such as deferred-tax adjustments, so operating results give a cleaner read than the bottom line alone. Because so much of the value hinges on how long LUPKYNIS holds exclusivity, any valuation is really a judgment on patent durability, sales growth, and whether the pipeline or a buyout adds value.

GSK. These figures are approximate, tied to the asOf date, and reported in a mix of pounds and dollars because GSK is a UK company trading as a US ADR, so verify live numbers before acting. GSK's lower multiple reflects slower growth and pipeline and litigation overhangs rather than a distressed balance sheet. The stock tends to behave like a value-and-income pharma holding, so the multiple matters less than whether new launches can offset patent expiries over time.

Headline figures (approximate, Jul 2026): AUPH shows business model Commercial-stage biopharma concentrated on one product, LUPKYNIS (voclosporin) for lupus nephritis, revenue trend Growing, with recent year-over-year growth roughly in the 20% to 34% range, driven by LUPKYNIS net product sales, profitability Profitable with positive operating cash flow, unusual for a small-cap biotech; some reported net income figures reflect one-time tax items, so read carefully, balance sheet Substantial cash and investments; has funded share repurchases and an acquisition; GSK shows revenue (ttm) approximately £31 to £32 billion, with vaccines, HIV, and specialty medicines the main contributors, operating margin reported around the mid-to-high 20s percent on an adjusted basis, typical of large-cap pharma, eps adjusted earnings per share reported in roughly the mid-single-digit dollars per ADR; verify the latest figure live, market cap approximately $105 to $110 billion (ADR traded around the low $50s in early 2026).

AUPH and GSK are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined AUPH and GSK exposure against your real portfolio. It is not an investment adviser.